The U.S. FDA announced on July 12 that it will add a warning to the fact sheet for Johnson & Johnson's (Janssen) COVID-19 vaccine stating that data suggests there is an increased risk of Guillain-Barre syndrome (GBS), a rare neurological disorder, in the six weeks after inoculation. The FDA identified 100 preliminary reports of GBS among the 12.8 million J&J vaccine recipients. The preliminary reports included 95 serious cases that required hospitalization and one reported death.
The chance of having this occur is rare. You should seek medical attention right away if you develop any of the following symptoms after receiving the Johnson & Johnson (Janssen) COVID-19 Vaccine:
- Weakness or tingling sensations, especially in the legs or arms, that’s worsening and spreading to other parts of the body
- Difficulty walking
- Difficulty with facial movements, including speaking, chewing, or swallowing
Double vision, or inability to move the eyes
Difficulty with bladder control or bowel function